Minimally invasive lung adenocarcinoma
MONDO:0004991A solitary adenocarcinoma arising from the lung measuring 3 cm or less. It is characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. It is usually a non-mucinous adenocarcinoma, but rarely may be mucinous.
Also known as: BAC, bac, bronchioalveolar adenocarcinoma of lung, bronchioalveolar adenocarcinoma of the lung, bronchioalveolar lung carcinoma, bronchiolo-alveolar carcinoma of lung, bronchiolo-alveolar carcinoma of the lung, bronchiolo-alveolar lung carcinoma
2807 clinical trials for this condition and its sub-types, 9 tagged with Minimally invasive lung adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Minimally invasive lung adenocarcinoma
-
New cocktail for tough lung cancer shows promise in small trial
Disease control OngoingThis phase 2 pilot trial tested adding the drug bevacizumab to standard chemotherapy and radiation for patients with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 29 newly diagnosed patients to see if the combination is safe and helps …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Could a new drug combo shrink tough lung tumors?
Disease control OngoingThis study tests whether adding the drug veliparib to standard chemotherapy and radiation helps people with stage III lung cancer that can't be removed by surgery. About 53 adults took part to find the best dose and see if the combination slows cancer growth. The goal is to impro…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Less invasive lung surgery may be as effective as full lobectomy
Disease control OngoingThis study compared two surgical approaches for early-stage lung cancer: removing the entire lobe (lobectomy) versus removing just the tumor with a small margin (sublobar resection). Over 700 patients with small peripheral tumors were randomly assigned to one surgery. The goal wa…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New combo therapy shows promise for early lung cancer
Disease control OngoingThis study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation therapy helps prevent lung cancer from coming back in people with early-stage non-small cell lung cancer. About 140 participants will receive either radiation alone or radiation plus…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC